NorthWest Biotherapeutics Inc (NWBO)

[Galzus Research]

So, some 40 patients defied death and entered an unproven trial on a glimmer of hope. Three died before the treatment had time to work.

This (a small group of patients having a Lazarus effect or some other unusually outstanding benefit) happens in almost every phase 1 trial. It's one reason JANX is so hyped right now.

Learningcurve has the right of it. If NWBO management had as much confidence in DCVax-Direct as the longs on this board, they would have moved it forward (into a registrational trial) starting almost 10 years ago.

There is no strategic explanation to just keep going with the status quo while you're able to raise funds against a billion-dollar market cap for years and years. The simplest explanation is that NWBO management sees these phase 1 data for what they are: a neat signal of something promising.